Our Database of anti-claudin therapeutic programs in oncology is available for free download here.
🔬 What’s inside?
✅ 43 preclinical & clinical programs targeting CLDN1, CLDN4, CLDN6, or CLDN18.2
✅ Multiple modalities: mAbs (8), bispecifics (14), antibody-drug conjugates (15), CAR T cells (5)
✅ Across clinical stages: Phase I (17), Phase II (4), Phase III (10)
Featuring anti-claudin programs from leading players, including:
Alentis Therapeutics, ABL Bio, Amgen, AskGene Pharma, Astellas, AstraZeneca, BeiGene, Beijing Mabworks Biotech, BeOne Medicines, BioNTech, Bristol Myers Squibb, CARsgen Therapeutics, Chugai Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology, CTTQ, Essen Biotech, Evopoint Biosciences, FutureGen Biopharmaceutical, I-Mab Biopharma, Innovent Biologics, Jiangsu Hengrui, Keymed Biosciences, LaNova Medicines, Legend Biotech, Qilu Pharmaceutical, QureBio, RemeGen, SOTIO, Suzhou Immunofoco Biotechnology, Third Arc Bio, TORL Biotherapeutics, Transcenta Therapeutics, Xencor, and Zai Lab.
Looking for a partner to advance your IO program?
Explicyte supports biotech, pharma, and AI players at every stage:
- Target discovery: We source human tumor specimens to identify and validate new therapeutic targets, leveraging multi-omic and spatial biology approaches.
- Preclinical development: With 10 years of experience assessing novel IO candidates—from hit-to-lead to pre-IND studies —we use advanced cellular models to document the efficacy, MoA and safety profile of your lead compound
- Clinical trials: ISO-certified for the development and testing of IHC/IHF-based biomarkers in clinical samples, we support patient selection and can also monitor early pharmacodynamic signals in peripheral samples.